buy discuss management highlight
confid pralsetinib avapritinib
messag spoke cfo michael landsittel vice-president corpor affair jim baker
sr ir manag kristin hodou recent ret kit inhibitor competitor news
takeaway selpercatinib pralsetinib continu look similar
differ efficaci safeti converg ripretinib avapritinib
like split gist market increas management confid avapritinib sm
posit head day focu key theme
role precis medicin indol sm landscap franchis opportun novel
target demonstr power platform maintain buy pt
post-wclc selpercatinib pralsetinib look similar differ
efficaci safeti signal continu converg accord peculiar
selpercatinib wclc dataset blend escal expans portion
trial contrast report expans cohort link
import distinct accord management given interact fda
note selpercatinib expansion-onli data could interest see particularli
context decreas confirm orr start wclc
link wclc link upon inclus dose expans patient
meanwhil pralsetinib confirm orr increas unconfirm orr
aacr confirm post-platinum expans cohort link
toxic profil management conced pralsetinib may caus sever
neutropenia grade rel selpercatinib also highlight latter higher
incid ast/alt liver enzym elev vs pralsetinib
respect increas grade hypertens bring in-lin
pralsetinib selpercatinib vs pralsetinib furthermor management note
present toxic entir safeti popul curiou nsclc-
subset ultim think drug well-toler
compani guid addit top-lin pralsetinib data disclosur via press releas
around time potenti nda file pralsetinib remain on-track
nda file pralsetinib pre-treat nsclc mtc respect compani
highlight acceler come updat expect
similarly-s data disclosur wclc present furthermor compani
reiter guidanc initi front-lin random ret nsclc trial ye
similar time left open possibl acceler front-lin
single-arm approv management caveat bar definit higher
emphas gist patient heavili pre-treat vs invictu
patient efficaci may similar strictli line set management felt
invictu efficaci result overal within expect ripretinib mpf
orr fall slightli respect highlight gist patient
receiv median prior line therapi wherea invictu cap
popul see management takeaway believ look
pure popul see similar differ sure drug
truli differenti efficaci perspect set
fundament avapritinib ripretinib differ molecul may occupi
differ segment kit-driven gist market split overal
opportun accord management overal management expect molecul replac
sutent stivarga bayri avapritinib ripretinib would ultim
use differ gist patient given differ molecular profil
pursuit biomark enrich addit expect
page analyst certif import disclosur
signific overlap patient like respond avapritinib vs
mention system mastocytosi sm could compani singl
attract opportun contrast ret tumor gist sm repres
opportun could outright given avapritinib efficaci stand alon without
real competit accord compani furthermor management believ exist
limit epidemiolog number sm uncertain probabl conserv
upcom day novemb focu key theme
evolut biomark ctdna test fit within ecosystem
avapritinib potenti role within indol sm overview diseas
includ relev clinic endpoint consist diseas epidemiolog overal
opportun addit opportun well novel target demonstr
power platform
updat estim account shift competit landscap maintain
buy rate pt maintain prior view pralsetinib
potenti competit profil rel neutral pralsetinib
despit latter potenti first-mov advantag modestli revis forecast
pralsetinib market share also includ front-lin ret nsclc
opportun move forecast launch time within gist reduc
forecast market share light buy strong invictu
readout continu forecast avapritinib split market ripretinib given
former pursuit biomark enrich strategi gist pursuit random
trial gist maintain buy rate pt
page analyst certif import disclosur
valuat risk
valu per share use dcf base valuat method
valuat includ probability-adjust cash flow deriv compani pipelin
includ avapritinib use discount rate termin growth rate
appli termin year post-assum gener entri lead pipelin candid
risk rate valuat includ regulatori commerci
setback potenti emerg new competitor lower product sale expect
page analyst certif import disclosur
total cost expens
interest incom net
loss extinguish debt
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
